190 related articles for article (PubMed ID: 18384446)
1. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
McGettigan P; Han P; Jones L; Whitaker D; Henry D
Br J Clin Pharmacol; 2008 Jun; 65(6):927-34. PubMed ID: 18384446
[TBL] [Abstract][Full Text] [Related]
2. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Hudson M; Rahme E; Richard H; Pilote L
Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
[TBL] [Abstract][Full Text] [Related]
3. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
[TBL] [Abstract][Full Text] [Related]
4. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Hudson M; Richard H; Pilote L
BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
6. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
7. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.
Page J; Henry D
Arch Intern Med; 2000 Mar; 160(6):777-84. PubMed ID: 10737277
[TBL] [Abstract][Full Text] [Related]
8. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
9. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Andersohn F; Schade R; Suissa S; Garbe E
Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
[TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
13. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
14. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
15. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Harley C; Wagner S
Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
[TBL] [Abstract][Full Text] [Related]
17. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
18. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
19. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]